- Home
- MITT vs LCTX Comparison
MITT vs LCTX Comparison
Compare MITT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITT
- LCTX
- Stock Information
- Founded
- MITT 2011
- LCTX 1990
- Country
- MITT United States
- LCTX United States
- Employees
- MITT N/A
- LCTX N/A
- Industry
- MITT Real Estate Investment Trusts
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MITT Real Estate
- LCTX Health Care
- Exchange
- MITT Nasdaq
- LCTX Nasdaq
- Market Cap
- MITT 230.0M
- LCTX 274.0M
- IPO Year
- MITT 2011
- LCTX N/A
- Fundamental
- Price
- MITT $7.22
- LCTX $1.76
- Analyst Decision
- MITT Strong Buy
- LCTX Strong Buy
- Analyst Count
- MITT 5
- LCTX 4
- Target Price
- MITT $8.50
- LCTX $4.25
- AVG Volume (30 Days)
- MITT 184.6K
- LCTX 1.8M
- Earning Date
- MITT 11-04-2025
- LCTX 11-13-2025
- Dividend Yield
- MITT 11.77%
- LCTX N/A
- EPS Growth
- MITT N/A
- LCTX N/A
- EPS
- MITT 0.86
- LCTX N/A
- Revenue
- MITT $83,509,000.00
- LCTX $10,914,000.00
- Revenue This Year
- MITT N/A
- LCTX N/A
- Revenue Next Year
- MITT $13.95
- LCTX $176.00
- P/E Ratio
- MITT $8.32
- LCTX N/A
- Revenue Growth
- MITT 25.02
- LCTX 76.43
- 52 Week Low
- MITT $5.63
- LCTX $0.37
- 52 Week High
- MITT $7.97
- LCTX $1.80
- Technical
- Relative Strength Index (RSI)
- MITT 36.72
- LCTX 69.14
- Support Level
- MITT $7.15
- LCTX $1.64
- Resistance Level
- MITT $7.47
- LCTX $1.77
- Average True Range (ATR)
- MITT 0.18
- LCTX 0.11
- MACD
- MITT -0.06
- LCTX -0.00
- Stochastic Oscillator
- MITT 10.84
- LCTX 75.00
About MITT AG Mortgage Investment Trust Inc.
AG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. It also focuses on investing in residential mortgage-backed securities (RMBS) issued or guaranteed by a government-sponsored enterprise.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.